Medication info
Valsartan 80 mg Tablet

Valsartan 80 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceuticals Co., Ltd.
Appearance
Light reddish round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200810314 · Notified 2008.10.10 · Insurance code 649505260

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
(Tablet) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg once daily of this medicine. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg once daily of this medicine. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg once daily of this medicine. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, start treatment with 40 mg once daily of this medicine; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. If administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher; however, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Unimed Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is primarily used for the management of essential hypertension and is effective in treating heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in patients with decreased left ventricular function following myocardial infarction. Based on these effects, it improves the heart health of patients and assists in the management after heart failure and myocardial infarction.

How to take

Adult dose

(Tablet) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg once daily of this medicine. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg once daily of this medicine. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg once daily of this medicine. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, start treatment with 40 mg once daily of this medicine; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. If administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher; however, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus during pregnancy, so it should be stopped immediately if pregnancy is confirmed. Women who are pregnant, may become pregnant, or are breastfeeding should not use this medication. Patients with severe liver dysfunction and severe kidney disease should also refrain from using this medication for safety. Patients with a history of allergic reactions or angioedema should be cautious as taking this medication may be risky. Elderly patients, those with hyperkalemia, and patients with mild liver dysfunction should have dosage adjustments and monitoring of their condition when using this medication. Patients after heart failure or myocardial infarction may need regular kidney function tests due to potential changes in kidney function. This medication lowers blood pressure, so hypotension can occur upon first use; if symptoms occur, consult a physician immediately. When used in conjunction with other antihypertensives or diuretics, the risk of side effects may increase, so consultation with healthcare professionals is necessary. Potassium levels may increase while taking this medication; therefore, patients at risk for hyperkalemia should consistently check potassium levels. Caution is necessary when driving or operating machinery due to potential dizziness. In case of overdose, symptoms like hypotension and decreased consciousness may occur, necessitating immediate contact with medical services for appropriate action. Safety in children and adolescents has not yet been established, so use is not recommended. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 50 more
  • stomachache
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • kidney damage
  • hyperkalemia
  • angioedema
  • arrhythmia
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • dry mouth
  • appetite loss
  • malaise
  • edema
  • redness
  • itching
  • serum sickness
  • vasculitis
  • hepatitis
  • syncope
  • epistaxis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • bullous dermatitis
  • decrease in hematocrit
  • decrease in hemoglobin
  • neutropenia
  • increased serum creatinine
  • increased total bilirubin
  • increased BUN
  • indigestion
  • anemia
  • tinnitus
  • hypertonia
  • reduced motor function
  • confusion
  • chest pain
  • rash
  • myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is recommended to keep it in a cool place below 30 degrees Celsius, avoiding direct sunlight and high temperatures. Storing in this manner helps maintain the medication's effectiveness for an extended period.

Appearance and packaging

Appearance

Light reddish round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.